Hemarthrosis, unspecified joint
Methodology & AI Transparency ⓘ
Hemarthrosis, unspecified joint Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Recognized across U.S.
- 2 Real-world patient consensus: Diagnostic registry M25.00: Hemarthrosis, unspecified joint is managed within Arthritis & Joints.
- 3 Typical cash cost range: Primary evaluation for Hemarthrosis, unspecified joint incorporates synovial fluid crystal/cell in Hemarthrosis, unspecified joint (M25.00: analysis when effused) and symptom diary review.
- 4 Top reported side effects / signs: Objective lab/clinical target for Hemarthrosis, unspecified joint: Weight-Bearing Joint Radiograph [Hemarthrosis, unspecified joint M25.00] (Preserved joint-space width (M25.00)) and Serum Uric Acid in Hemarthrosis, unspecified joint (M25.00: (Gout Target)).
Ask our AI Specialists anything about Hemarthrosis, unspecified joint
What Is Hemarthrosis, unspecified joint?
Recognized across U.S. clinical coding as M25.00 (Arthritis & Joints), Hemarthrosis, unspecified joint is evaluated via synovial fluid crystal/cell in Hemarthrosis, unspecified joint (M25.00: analysis when effused) to align day-to-day symptom relief with long-term physiological stability.
Pathophysiology, Underlying Causes & Clinical Presentation
At the cellular and tissue level in arthritis & joints, Hemarthrosis, unspecified joint (M25.00) involves monosodium urate or in Hemarthrosis, unspecified joint (M25.00: calcium pyrophosphate crystal). progression correlates with shifts in Weight-Bearing Joint Radiograph [Hemarthrosis, unspecified joint M25.00] (Preserved joint-space width (M25.00)).
Common Symptoms & Clinical Signs
- • Presentation of Hemarthrosis, unspecified joint (M25.00): brief morning joint in Hemarthrosis, unspecified joint (M25.00: stiffness)
- • Secondary Hemarthrosis, unspecified joint clinical sign: sudden, intensely painful, in Hemarthrosis, unspecified joint (M25.00: red swollen big-toe)
- • Symptom flares in Hemarthrosis, unspecified joint correlating with Weight-Bearing Joint Radiograph [Hemarthrosis, unspecified joint M25.00] deviation outside Preserved joint-space width (M25.00)
- • Functional arthritis & joints impact requiring synovial fluid crystal/cell in Hemarthrosis, unspecified joint (M25.00: analysis when effused) evaluation (M25.00)
Hemarthrosis, unspecified joint Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | M25.00 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Osteoarthritis, Gout & Joint Pain | NLM Clinical Tables |
| Diagnostic / Lab Marker: Weight-Bearing Joint Radiograph [Hemarthrosis, unspecified joint M25.00] | Preserved joint-space width (M25.00) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Serum Uric Acid in Hemarthrosis, unspecified joint (M25.00: (Gout Target)) | < 6.0 mg/dL (< 5.0 mg/dL with tophi) (M25.00) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: hs-CRP & Erythrocyte in Hemarthrosis, unspecified joint (M25.00: Sedimentation Rate) | hs-CRP < 1.5 mg/L; ESR < 15 mm/hr (M25.00) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Hemarthrosis, unspecified joint
Treatment selection for Hemarthrosis, unspecified joint depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Hemarthrosis, unspecified joint)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on A Phase 3, 56-week, randomised, gold-standard blind, compared against a dummy: What a 513-Participant Study Found 513 patients were randomised. Clinical and experimental rheumatology • 2025-05-15 • Phase III Randomized Trial | N = 513 | 93/100 | PMID 39808286 ↗ |
| New Insights on Benefits and safety of risankizumab for active psoriatic arthritis: 24-week: What a 444-Participant Study Found Treatment with risankizumab resulted in significant improvements versus placebo in key disease outcomes and was well tolerated in patients with PsA who were Bio-IR and/or csDMARD-IR. Annals of the rheumatic diseases • 2022-03-15 • Phase III Randomized Trial | N = 444 | 93/100 | PMID 34815219 ↗ |
| Can This Approach Help? Inside the Latest Research on Real-world benefits and safety of LBAL, a candidate adalimumab biosimilar, and LBAL was equivalent in efficacy and comparable in safety, including immunogenicity, to ADL. Clinical and experimental rheumatology • 2022-05-15 • Phase III Randomized Trial | N = 191 | 88/100 | PMID 34251303 ↗ |
| Can This Approach Help? Inside the Latest Research on Efficacy, how the body absorbs the medicine and safety of subcutaneous versus CT-P13 s.c. Rheumatology (Oxford, England) • 2021-05-14 • Phase III Randomized Trial | N = 167 | 88/100 | PMID 33230526 ↗ |
Hemarthrosis, unspecified joint Patient Community & “People Like Me” Threads
Filter Hemarthrosis, unspecified joint community threads and patient logs by age, biological sex, dosage, and treatment duration.